HCW Biologics Inc. is a clinical-stage biopharmaceutical company developing immunotherapies targeting chronic inflammation and age-related diseases. The company's pipeline centers on bifunctional and fusion protein therapeutics designed to modulate immune responses across multiple disease areas. Its lead candidate, HCW9218, has progressed through Phase 1 testing in chemotherapy-refractory solid tumors and Phase 1b/2 in pancreatic cancer. HCW9302, an IL-2 fusion protein complex, is in Phase 1 development for autoimmune and inflammatory conditions including alopecia areata. The company also maintains preclinical programs in natural killer cell therapy, immune checkpoint inhibition, and cell-based treatments.
HCW Biologics operates through internal development and collaborative arrangements. The company holds license agreements with Wugen Inc. for cell therapy-based treatments and with WY Biotech Co., Ltd. for preclinical molecule development and co-development rights. These partnerships provide access to complementary technology platforms and expand the company's therapeutic scope.
As of its latest reporting, the company operates with 36 full-time employees and is headquartered in Miramar, Florida. Incorporated in Delaware in 2018, HCW Biologics is listed on Nasdaq. The company is pre-revenue and dependent on capital to fund clinical development and operations.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-0.77 | $-0.77 | -10.0% | |
| 2023 | $-0.70 | $-0.70 | -66.7% | |
| 2022 | $-0.42 | $-0.42 | — | |
| 2021 | — | — | — |